Article Text

Download PDFPDF
Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease
  1. Maurizio Pocchiari,
  2. Anna Ladogana
  1. Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
  1. Correspondence to Professor Maurizio Pocchiari, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome 161, Italy; maurizio.pocchiari{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Compassionate use of doxycycline, a tetracycline antibiotic, in patients with Creutzfeldt-Jakob disease (CJD) revealed an increased survival of 4–7 months as compared with historical controls, a result not confirmed by a randomised, double blind, placebo-controlled trial.1 Is then therapy with doxycycline for patients with CJD over? The report of Assar et al2 on a single patient with variably protease-sensitive prionopathy (VPSPr),3 a rare subtype form of sporadic CJD, who received 4-year treatment with doxycycline at a relatively early stage of disease, suggests it is not and encourages novel studies on the use of doxycycline in prion diseases. The patient, who carried the commonly VPSPr-associated valine homozygosity …

View Full Text


  • Contributors MP and AL contributed to drafting of the manuscript and in critically revising it.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • PostScript
    Hamid Assar Raffi Topakian Serge Weis Jasmin Rahimi Johannes Trenkler Romana Höftberger Fahmy Aboulenein-Djamshidian Thomas Ströbel Herbert Budka Helen Yull Mark W Head James W Ironside Gabor G Kovacs